Galangin inhibits human osteosarcoma cells growth by inducing transforming growth factor-β1-dependent osteogenic...

Area of Science:

• Oncology
• Natural Products Chemistry
• Molecular Biology

Background:

• Osteosarcoma is the most common primary bone cancer, characterized by uncontrolled osteoblast proliferation and poor differentiation.
• Current treatments like chemotherapy and radiotherapy offer limited efficacy for osteosarcoma.
• There is a critical need for novel therapeutic agents with improved effectiveness and reduced side effects.

Purpose of the Study:

• To investigate the anti-cancer effects of galangin, a natural flavonoid, on human osteosarcoma cells.
• To evaluate galangin's potential to induce osteogenic differentiation in osteosarcoma cells.
• To elucidate the molecular mechanism underlying galangin's bioactivity, focusing on the transforming growth factor (TGF)-β1/Smad2/3 signaling pathway.

Main Methods:

• In vitro studies using human osteosarcoma cell lines to assess proliferation and apoptosis.
• Analysis of osteoblast differentiation markers (collagen type I, alkaline phosphatase, osteocalcin, osteopontin) and alkaline phosphatase activity.
• In vivo studies to evaluate galangin's effect on osteosarcoma tumor growth.
• Pathway blocking experiments to confirm the involvement of the TGF-β1/Smad2/3 signaling pathway.

Main Results:

• Galangin significantly inhibited human osteosarcoma cell proliferation without inducing significant apoptosis.
• Galangin markedly enhanced the expression of key osteoblast differentiation markers and increased alkaline phosphatase activity.
• In vivo studies demonstrated that galangin attenuated osteosarcoma growth.
• Galangin's effects were attributed to the selective activation of the TGF-β1/Smad2/3 signaling pathway.

Conclusions:

• Galangin exhibits significant anti-proliferative and osteogenic differentiation-inducing effects on human osteosarcoma cells.
• Galangin demonstrates therapeutic potential for osteosarcoma treatment, both in vitro and in vivo.
• Targeting the TGF-β1 pathway to induce osteogenic differentiation represents a promising therapeutic strategy for osteosarcoma with potentially minimal side effects.